



EXPRESS MAIL NO.: EV 452 775 546 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Muller et al.	Confirmation No.:	2627
Application No:	10/622,618	Group Art Unit:	1614
Filed:	July 17, 2003	Examiner:	R. Anderson
For:	NOVEL IMMUNOTHERAPEUTIC AGENTS	Attorney Docket No.:	9516-200-999 (CAM: 501872-999199)

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references **A01 to A74, B01 to B15, and C01 to C37** listed on the attached form PTO 1449 entitled "List of References Cited by Applicant." The above identified application is a continuation of U.S. application Serial No. 10/243,927, filed September 13, 2002. Pursuant to 37 C.F.R. § 1.98(d), copies of the listed references **A01 to A74, B01 to B15, and C01 to C37** have not been included herein as such copies are available in parent application Serial No. 10/243,927, filed September 13, 2002. Applicant will provide copies of the references upon request by the Examiner.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(4) because this Information Disclosure Statement is being filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114, no fee is believed to be due. Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. 50-3013.

Date: June 27, 2005

Respectfully submitted,
Anthony M. Insogna, Reg. No. 35,203
By: *Mitchell J. Brenner, Reg. No. 47,458* 35,203
Anthony M. Insogna (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)

ATTY DOCKET NO.

9516-200-999

APPLICATION NO.

10/622,618

APPLICANT

Muller et al.

FILING DATE

July 17, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	60/436,975		Muller et al.			12/30/02
	A02	60/438,448		Muller et al.			1/7/03
	A03	60/438,450		Muller et al.			1/7/03
	A04	60/452,460		Muller et al.			3/5/03
	A05	60/454,149		Man et al.			3/12/03
	A06	10/316,673		Muller et al.			12/11/02
	A07	10/748,085		Man et al.			12/29/03
	A08	10/900,270		Muller et al.			7/28/04
	A09	10/900,332		Muller et al.			7/28/04
	A10	10/934,974		Muller et al.			9/3/04
	A11	2001/056107	12/27/01	Muller et al.			
	A12	2003/0045726	3/6/03	Muller et al.			
	A13	2003/0187052	10/2/03	Muller et al.			
	A14	2004/006096	1/8/04	Muller et al.			
	A15	2004/0019106	1/29/04	Muller et al.			
	A16	2004/0147588	7/29/04	Man et al.			
	A17	2004/0167174	8/26/04	Man et al.			
	A18	2004/0167199	8/26/04	Muller et al.			
	A19	2004/0204448	10/14/04	Man et al.			
	A20	2004/0254214	12/16/04	Muller et al.			
	A21	2004/0259873	12/23/04	Man et al.			
	A22	2005/0014727	1/20/05	Muller et al.			
	A23	3,536,809	10/27/70	Applezweig			
	A24	3,598,123	8/10/71	Zaffaroni			
	A25	3,845,770	11/5/74	Theeuwes et al.			
	A26	3,916,899	11/4/75	Theeuwes et al.			
	A27	4,008,719	2/22/77	Theeuwes et al.			
	A28	4,492,708	1/8/85	Spitzer			
	A29	5,059,595	10/22/91	La Grazie			
	A30	5,073,543	12/17/91	Marshall et al.			

	A31	5,120,548	6/9/92	McClelland et al.			
	A32	5,354,556	10/11/94	Sparks et al.			
	A33	5,414,008	5/9/95	Muller et al.			
	A34	5,463,063	10/31/95	Muller			
	A35	5,580,888	12/3/96	Warrelow et al.			
	A36	5,591,767	1/7/97	Mohr et al.			
	A37	5,605,914	2/25/97	Muller			
	A38	5,632,984	5/27/97	Wong et al.			
	A39	5,639,476	6/17/97	Oshlack et al.			
	A40	5,658,940	8/19/97	Muller et al.			
	A41	5,674,533	10/7/97	Santus et al.			
	A42	5,698,579	12/16/97	Muller			
	A43	5,703,098	12/30/97	Muller			
	A44	5,728,844	3/17/98	Muller			
	A45	5,728,845	3/17/98	Muller			
	A46	5,733,566	3/31/98	Lewis			
	A47	5,736,570	4/7/98	Muller			
	A48	5,770,589	6/23/98	Billson			
	A49	5,801,195	9/1/98	Muller et al.			
	A50	5,877,200	3/2/99	Muller			
	A51	5,929,117	7/27/99	Muller et al.			
	A52	5,968,945	10/19/99	Muller et al.			
	A53	6,001,368	12/14/99	Jenks			
	A54	6,011,050	1/4/00	Muller et al.			
	A55	6,015,803	1/18/00	Wirostko			
	A56	6,020,358	1/4/00	Muller et al.			
	A57	6,046,221	4/4/00	Muller et al.			
	A58	6,075,041	6/13/00	Muller			
	A59	6,130,226	10/10/00	Muller et al.			
	A60	6,180,644	1/30/01	Muller et al.			
	A61	6,200,987	3/13/01	Muller			
	A62	6,214,857	4/10/01	Muller et al.			
	A63	6,218,369	4/17/01	Bombardelli et al.			
	A64	6,225,348	5/1/01	Paulson			
	A65	6,262,101	7/17/01	Muller et al.			
	A66	6,284,780	9/4/01	Muller et al.			
	A67	6,326,388	12/4/01	Man et al.			
	A68	6,429,221	8/6/02	Muller et al.			

	A69	6,479,554	11/12/02	Muller et al.			
	A70	6,518,281	2/11/03	Muller et al.			
	A71	6,656,964	12/2/03	Muller et al.			
	A72	6,699,899	3/2/04	Man et al.			
	A73	6,667,316	12/23/04	Man et al.			
	A74	6,844,359	1/18/05	Muller et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	EP 0091795	10/19/83	Europe				
	B02	EP 0316594	5/24/89	Europe				
	B03	EP 0 626 957	7/12/94	EP				
	B04	JP 05066591	3/19/93	Japan				
	B05	JP 58188868	11/4/83	Japan				
	B06	WO 95/01348	1/12/95	PCT				
	B07	WO 97/08143	3/6/97	PCT				
	B08	WO 97/23457	7/3/97	PCT				
	B09	WO 98/06692	2/19/98	PCT				
	B10	WO 99/06041	2/11/99	PCT				
	B11	WO 00/01387	1/13/00	PCT				
	B12	WO 01/34606	5/17/01	PCT				
	B13	WO 01/45702	6/28/01	PCT				
	B14	WO 03/080048	10/2/03	PCT				
	B15	WO 03/080049	10/2/03	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Bedford et al. 1996, Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4. Bioorganic & Medicinal Chemistry Lett. 6(2):157-160
	C02	Chen et al., 2000, Preparation of New Anti-Tubulin Ligands through a Dual-Mode, Addition-Elimination Reaction to a Bromo-Substituted α , β -Unsaturated Sulfoxide. J. Org. Chem. 65:8811-8815
	C03	Corral, L.G. et al., 1999, "Immunomodulation by thalidomide and thalidomide analogues," Ann. Rheum. Dis. 58 Suppl 1:1107-113
	C04	Cummins et al., 1971, Aust. J. Chem., v. 24(11), pp. 2257-2266
	C05	Cushman et al., 1993, Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J Med Chem. 35(12):2293-2306
	C06	Danion et al., 1972, Tetrahedron, v. 28(15), pp. 4223-4229 (including English language abstract)
	C07	Fischer et al., 1993, J. Organomet. Chem., v. 454(1-2), pp. 133-149 (including English language abstract)
	C08	Gwaltney et al., 2001, Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg Med Chem Lett. 11(7):871-874

C09	Hamel E. 1996, Antimitotic natural products and their interactions with tubulin. <i>Med Res Rev.</i> 16(2):207-231
C10	Hastie SB. 1991, Interactions of colchicine with tubulin. <i>Pharmacol Ther.</i> 51(3):377-401
C11	Ilg et al., 2001, <i>Organometallics</i> , v. 20(17), pp. 3782-3794
C12	Laubender et al., 1998, <i>Angewandte Chemie, Int. Ed.</i> , v. 37(1/2), pp. 150-152
C13	Laubender et al., 1999, <i>Chemistry-A European Journal</i> , v. 5(10), pp. 2937-2946
C14	Li et al., 2002, Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. <i>Bioorg Med Chem Lett.</i> 12(3):465-469
C15	Liou et al., 2002, Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. <i>J Med Chem.</i> 45(12):2556-2562
C16	Luduena et al., 1991, Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. <i>Pharmacol Ther.</i> 49(1-2):133-152
C17	McGown and Fox, 1990, Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. <i>Cancer Chemother Pharmacol.</i> 26(1):79-81
C18	Medarde et al., 1999, Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. <i>Bioorg Med Chem Lett.</i> 9(16):2303-2308
C19	Mu et al., 2001, Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization. <i>J Med Chem.</i> 44(3):441-452
C20	Nam et al., 2002, Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues. <i>Bioorg Med Chem Lett.</i> 12(15):1955-1958
C21	Ohsumi et al., 1998, Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. <i>J Med Chem.</i> 41(16):3022-3032
C22	Ohsumi et al., 1998, Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. <i>Bioorg Med Chem Lett.</i> 8(22):3153-3158
C23	Pac et al., 1984, <i>J. Org. Chem.</i> , v. 49(1), pp. 26-34 (1984)
C24	Pettit et al., 2002, Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. <i>J Med Chem.</i> 45(12):2534-2542
C25	Pettit et al., 2000, Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. <i>J Med Chem.</i> 43(14):2731-2737
C26	Pettit et al., 1999, Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4. <i>J Med Chem.</i> 42(8):1459-1465
C27	Pettit et al., 1998, Antineoplastic agents. 379. Synthesis of phenstatin phosphate. <i>J Med Chem.</i> 41(10):1688-1695
C28	Pettit et al., 1989, Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. <i>Experientia.</i> 45(2):209-211
C29	Profitt et al., 1975, A Reagent for the α , β Reduction of Conjugated Nitriles. <i>J. Org. Chem.</i> , 40(1), pp. 127-128
C30	Shirai et al., 1998, Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. <i>Bioorg Med Chem Lett.</i> 8(15):1997-2000
C31	Thorpe PE, 2004, Vascular targeting agents as cancer therapeutics. <i>Clin Cancer Res.</i> 10(2):415-427
C32	Update on Spindle Poisons - Part II: Vinca Alkaloids and Analogs/Formulations. <i>Future Oncology</i> , Vol. 6 (12):1457-1484 (2002)
C33	Update on Spindle Poisons - Part III: Novel Agents in Development. <i>Future Oncology</i> , 7 (1/2):1485-1528 (2002)

	C34	Verdier-Pinard et al., 1998, Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol. 53(1):62-76
	C35	Wang et al., 2002, Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem. 45(8):1697-1711
	C36	Wolff, ed., 1995, <i>Burger's Medicinal Chemistry and Drug Discovery</i> , 5 th ed., pp. 172-178, 949-982
	C37	Yoon et al., 2002, CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. Mol Cancer Ther. 1(6):393-404
EXAMINER		DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		